Published 05:11 IST, October 15th 2020

UN stresses on WHO clearance for COVID-19 vaccines, Russia's Sputnik V included

UN spokesperson Stephane Dujarric said on Wednesday that any vaccine for the COVID-19 infection must be cleared by the World Health Organisation.

Reported by: Sounak Mitra
Follow: Google News Icon
  • share
null | Image: self
Advertisement

dressing a press conference on Wednesday, October 14 United Nations spokesperson Stephane Dujarric said that any vaccine for COVID-19 infection must be cleared by World Health Organisation. Earlier in September, Russian President Vlimir Putin in his speech at UN General Assembly h said that he will provide free Sputnik V vaccines to all UN staff worldwide. 

RE: European Union Agrees To Slap Sanctions On Russian Officials Over Navalny Attack

Advertisement

"Those discussions are ongoing." "For us, it's important that any vaccine be cleared by WHO, but discussions are ongoing", said Stephane Dujarric. 

In August, Russia h anunced that it h developed world's first registered vaccine named Sputnik V. vaccine registration raised concerns among Western scientists as COVID-19 vaccine developed by Moscow's Gamaleya research centre h received approval before clinical trials h been completed.

RE: Russia Approves Second Virus Vaccine After Early Trials

Advertisement

First registered COVID-19 vaccine

After anuncing world's first registered COVID-19 vaccine, Russia is reported to have begun early clinical trials for a second COVID-19 vaccine. According to vaccine developer, early clinical trials of a second Russian COVID-19 vaccine have proved successful. 

Earlier on October 1, Vektor, Russia's state virology research centre in Siberia, said that early-st trials were successful for its own experimental vaccine, named 'EpiVacCorona'. first two phases of clinical trials demonstrated effectiveness and safety of EpiVacCorona vaccine, Vektor's press department told a Russian news ncy. 

Advertisement

post-registration clinical trials would begin with 5,000 volunteers in Siberia, Vektor said and ded that re would be a separate clinical trial involving 150 volunteers who are over 60 years of . Furr, lab will begin placebo-controlled trials on 5,000 Russian volunteers between s of 18 and 60. Russia plans to manufacture an initial 10,000 doses and production is expected to begin in vember, Vektor informed.

RE: Vlimir Putin Calls For Boost In Production Of Two Russian COVID-19 Vaccines

Advertisement

RE: Armenia-Azerbaijan Conflict: Russia Urges Both Countries To Hor Ceasefire Agreement

(With ANI Inputs)

Advertisement

05:11 IST, October 15th 2020